Attovia Therapeutics Surges in Nasdaq Debut Following Upsized $332M IPO

Key Facts

In a move reflecting growing investor appetite for the biotechnology sector, Attovia Therapeutics made a strong debut on the Nasdaq exchange. The company completed its initial public offering by selling 19.55 million shares at a price of $17.00 per share, exceeding initial plans. According to reports, the IPO generated approximately $332.40 million in gross proceeds following an upsize and the exercise of the over-allotment option by underwriters.

The stock of the company, which focuses on immune system treatments via its ATTOBODY platform, began trading at $21.00, marking a significant premium over the offering price. This momentum is driven by strong demand for the company's technologies licensed from Alamar Biosciences. Per analyst data, the decision to upsize the offering indicates the market's readiness to absorb clinical-stage issuances despite broader sector volatility.

Looking at the price action, the stock reached highs of $22.05 during early trading before settling near $20.38 as of August 6, 2026. With authoritative real-time price data currently unavailable in the database for this ticker, traders are monitoring the sustainability of these gains above the $17.00 IPO price as a key support level, while awaiting further clinical developments that may serve as future catalysts.